Loading stock data…
Eli Lilly and Company (LLY)
$1149.36-10.24 (-0.88%)
Market ClosedLast close Sep 4
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eli Lilly and Company in the Healthcare sector is trading at $1,149.36 with a market capitalization of $1.1T. Wall Street consensus targets $1,315.56 (29 analysts), implying a +14.5% move over the next 12 months. The stock is currently 11% below its 52-week high of $1,292.65, remaining 8.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.80B↑ | $19.29B↑ | $17.60B↑ | $15.56B↑ | $12.73B |
| Gross Profit | $16.22B↑ | $15.92B↑ | $14.59B↑ | $13.11B↑ | $10.50B |
| Operating Income | $9.78B↑ | $8.99B↑ | $8.39B↑ | $7.02B↑ | $5.30B |
| Net Income | $7.40B↑ | $6.64B↑ | $5.58B↓ | $5.66B↑ | $2.76B |
Peer Comparison
JNJUNHPFE
Fundamentals
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.11T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
42.93
Beta
Defensive asset. Lower volatility than the S&P 500.
0.51
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.58%
ROE
Elite ROE. Management converts capital into profit efficiently.
78.84%
Volume
Today's trading volume
2.16M
Recent News
Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
Eli Lilly and Company’s (NYSE:LLY) Mounjaro has already become a major growth driver in diabetes treatment, and its latest FDA approval could strengthen that position by expanding what physicians can use the drug to accomplish. The FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who […]
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.
Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock.
Michael Burry remains bullish on Veeva but trimmed his stake after shares jumped more than 15% on a fiscal second-quarter earnings beat and a raised 2027 outlook.
Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
Trump's latest MFN drug-pricing deals create a mixed outlook for the broader healthcare sector ETFs.
Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.